Allogene Therapeutics Inc (NAS:ALLO)
$ 2.02 -0.12 (-5.61%) Market Cap: 448.70 Mil Enterprise Value: 252.75 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 36/100

Allogene Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 08:40PM GMT
Release Date Price: $28.19 (+0.75%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone, from the JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce our next company, Allogene Therapeutics and CEO, David Chang. Please note that following this presentation, we'll have a Q&A session where you have the ability to submit questions via your conference portal.

So with that, David, thanks for being here today, and let me turn things over to you.

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Cory, thank you very much for the introduction, and happy new year. Good afternoon. I'm David Chang, CEO and Co-Founder of Allogene, a company dedicated in leading the next revolution in cell therapy.

If we can go to Slide 3? It's great to kick off 2021, updating our investors and supporters about the progresses at Allogene and how we intend to continue to grow Allogene to success throughout

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot